Abstract: A polymeric surfactant for use in chemical enhanced oil recovery, including a terpolymer of a first non-ionic monomer, a second non-ionic monomer, and an ionic monomer, the first non-ionic monomer being a hydrophilic monomer and the second non-ionic monomer being a hydrophobic monomer, the ionic monomer being in a lower proportion than the first and second non-ionic monomers. A method of preparation of polymeric surfactants.

Abstract: A detector of thermal neutrons, fast neutrons and gamma photons that is based on a Cherenkov radiation detector in water and that allows large active volumes of detection at a relatively low cost and higher intensity signals, wherein said detector comprises a container comprising at least a lid; a photon reflective and diffusive coating inside the container; an aqueous solution contained in the container, which comprises sodium chloride (NaCl); and a light sensing device optically coupled to the aqueous solution.

Abstract: A method of treating different fibrosis such as liver fibrosis, lung fibrosis or skin fibrosis, wound healing and skin rejuvenation is disclosed by administering a fusion protein having a soluble type II TGF-receptor bound to a stabilizing agent.

Abstract: Acrylamide-derived hydrogels and methods of fabrication thereof from an acrylic monomer, a crosslinking agent comprising an organosilicon compound, a polymerization initiator, a solvent and a polymerization accelerator, as well as their use in controlling circulation losses. The obtained hydrogels interact with the walls of the reservoir and exhibits an increase in viscosity, either at delayed times or in response to a given stimulus, such as changes in temperature, pressure, pH, salinity, using a simple and easily scalable methodology.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Abstract: A formulation and a composition that comprises it for promoting the pollination of pear crops (Pyrus) by biasing the foraging preferences of the honey bee (Apis mellifera). The formulation comprises the compounds limonene, linalool and ?-pinene. Additionally, a method for targeting the bees' pollination activity towards the pear crops by using the formulation comprising the compounds limonene, linalool and ?-pinene.

Abstract: Methods of detecting presence of a virus in a sample are provided, the method including contacting the sample with a solid state nanopore comprising a plurality of virus-specific aptamers and measuring a current-voltage curve in the solid state nanopore, wherein a decrease in the current indicates presence of the virus in the sample. Solid state nanopores comprising a plurality of virus-specific aptamers covalently linked to the interior of the solid state nanopore are also provided. Membranes including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers and kits and systems with a membrane including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers are also provided.

Abstract: Pyrometallurgic process for obtaining lithium compounds and intermediates, the process being characterized by comprising the steps of a) contacting lithium aluminosilicate particles with at least a fluorine solid compound, b) heating until a temperature of 25 to 900° C. obtaining a solid mixture and c) carrying out at least a leaching process of the mixture in step b).

Abstract: A method and device for detection of solid organic matter and fluids in a shale rock by means of low field Nuclear Magnetic Resonance (NMR) in a single measurement, by submitting a rock sample to a 2D NMR assay comprising applying a 2D pulse sequence with a saturation-recovery, or inversion-recovery, in an indirect dimension and an FID-CPMG in a direct dimension. The method can be used as an analytical technique for rock samples from unconventional hydrocarbon reservoirs.

Abstract: A glycoside compound of fatty acids that includes the general formula: GalNAc-GalNAc-Glc-O—R, where GalNAc is ?- or ?-D-N-acetylgalactosamine, Glc-O—R is a molecule of ?- or ?-D-glucose esterified to a monounsaturated fatty acid (R), where R is selected from 12:1(n) and where n is an integer between 2 and 11; 11:1(n) and where n is an integer between 2 and 10; 10:1(n), and where n is an integer between 2 and 9; 9:1(n), and where n is an integer between 2 and 8; 8:1(n), and where n is an integer between 2 and 8; 7:1(n) and where n is an integer between 2 and 7; and 6:1(n), and where n is an integer between 2 and 6. The compound has activity against plant pathogens, and induces the defense, and promotes the growth, of plants.

Abstract: The invention relates to methods for improving abiotic stress tolerance (and/or yield) in plants, including enhanced drought tolerance. It discloses nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing the same, and methods of using the same for increasing abiotic stress tolerance (and/or yield).

Abstract: A device and method for testing a rock specimen in order to determine the fracture toughness (KIC) thereof. The device comprises: a frame; a hydraulic pressure testing rig supported by the frame and comprising a pressure gauge, a lever and a pressure diaphragm; a storage tank for storing hydraulic fluid and supported by the frame; and a pressure chamber supported by the frame, in which the test specimen is placed to be subjected to hydrostatic pressure through conduits that connect said pressure chamber with the storage tank in fluid communication.

Abstract: Disclosed is a bioinsecticide formulation comprising highly resistant Beauveria bassiana microsclerotia and to its use for insect control, in particular for control of insects in grain silos, and to a method of preparation of said formulation. The microsclerotia are obtained in a culture medium comprising an iron (II) compound at a concentration of approximately 0.2 g/L.

Abstract: The present invention generally relates to the field of genetic engineering and obtaining transgenic traits for agronomic applications. More specifically, the present invention relates to a specific transgenic event in agricultural crops that improves plant characteristics. Yet more specifically, the invention relates to a polynucleotide construct comprising a gene from Arabidopsis thaliana. In particular, the polynucleotide construct of the invention comprises the gene AtBBX21 which encodes a B-box protein from Arabidopsis thaliana. The transgenic event of the invention increases green and seed yield, reduces photoinhibition, improves water use efficiency, increases tuber and chlorophyll production and improves photosynthetic rates, among others. The polynucleotide construct of the invention comprises a sequence depicted as SEQ ID NO: 1. The invention also provides a transgenic plant transformed with said polynucleotide construct, wherein said plant exhibits improved characteristics.

Abstract: Method for preventing or treating neuropathic and/or inflammatory pain, wherein said method comprises administering at least one effective dose of the phosphorothioate oligonucleotide IMT504. The preventive method may be applied to a mammal to be subjected to a medical or surgical intervention, or to a mammal that may be injured performing a risky task (for example, a soldier in a battle) to prevent development of pain after a medical intervention or injury.

Abstract: A method for the treatment of post-surgical pain in a patient. The method includes: a) administering at least one effective dose of the phosphorothioate oligonucleotide IMT504 to a mammal prior the surgery. The oligonucleotide IMT504 has the nucleotide sequence set forth in SEQ ID No. 1 and b) post-surgery administer a suboptimal amount of an opioid.

Abstract: The present invention relates to modified bacterial polypeptides having immunomodulatory and immunostimulatory activity. Most specifically, the present invention relates to modified bacterial polypeptides having an amino acid sequence selected from SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. The modified polypeptides are the adjuvant components of a pharmaceutical composition for eliciting an immune response against an specific antigen present in the pharmaceutical composition. In a preferred embodiment, the invention provides a pharmaceutical composition for a vaccine which comprises an adjuvant component which is any one of the modified polypeptides, one or more antigens, together with a pharmaceutically acceptable excipient.

Abstract: A pharmaceutical composition for topical wound treatment comprising one or more nitrogenous heterocyclic compound of 5 or 6 atoms with imide group; one or more deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and one or more carboxylic acid; kits and process to obtain this pharmaceutical composition and uses for wounds treatment.

Abstract: The invention relates to a pharmaceutical composition soluble in an aqueous solution, which is characterised in that it comprises sialoglycosphingolipids; polypeptides selected from the group comprising antibodies, fragments and variants of same; and at least one therapeutically active substance, forming a ternary micellar complex of sialoglycosphingolipid-therapeutically active substance-polypeptide in which the polypeptides are non-covalently associated with the micelles formed by the sialoglycosphingolipid and the therapeutically active substance.

Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided comprising an isoform of the TGF beta II receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.